News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Business Standard Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides an analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), focusing on momentum shifts and potential trading strategies based on AI models. It highlights strong near and mid-term sentiment, identifies compelling upside potential due to the absence of resistance levels, and offers specific …
This article provides the options chain for ORIC Pharmaceuticals, Inc. (ORIC), including call and put options with various strike prices and expiration dates. It details last trade dates, prices, bids, asks, volume, open interest, and implied volatility for contracts expiring on February 19, 2027. …
The article displays the "Price to book forward" for Oric Pharmaceuticals, Inc. (HAM:4TZ) on the Hamburg Stock Exchange. It indicates that the market was closed with no trades recorded for the period. The content provides a snapshot of financial data related to this specific …
ORIC Pharmaceuticals (ORIC) has garnered attention after reporting Q2 2026 results, showing wider net losses but improved basic loss per share, alongside significant share price momentum. The company's price-to-book ratio of 3.7x is below its direct peer average but above the broader US Biotechs …
H.C. Wainwright increased its price target for ORIC Pharmaceuticals (NASDAQ:ORIC) to $27 from $25, maintaining a Buy rating, citing a catalyst-rich second half of 2026 for the biopharmaceutical company. ORIC is expected to provide updates on its ORIC-944 program and present new data for …
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) has received a "Moderate Buy" consensus recommendation from sixteen brokerages, with an average 12-month price target of $19.27. Despite missing its last quarterly earnings estimate, institutional investors hold a significant portion of ORIC shares, and several research firms have recently …
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) announced inducement grants to two new employees. These grants include non-statutory stock options to purchase 32,500 shares of common stock and restricted stock units (RSUs) representing the right to receive 15,000 shares of common stock. The grants were made …
ORIC Pharmaceuticals reported widening net losses but improving per-share losses in the second quarter and first half of 2026, primarily due to a larger share count. The company remains a high-risk biotech story, relying on its oncology pipeline and continued equity financing, with future …
Evercore ISI analyst Cory Kasimov has maintained a Buy rating on Oric Pharmaceuticals (ORIC) with a price target of $25.00. Kasimov has a strong track record in the Healthcare sector, and Oric Pharmaceuticals holds a consensus "Strong Buy" rating from analysts. The company recently …
Oric Pharmaceuticals (NASDAQ:ORIC) saw its shares rise by 12.3% in midday trading on Tuesday, despite a significant drop in trading volume and a recent earnings miss. The company maintains a "Moderate Buy" consensus rating from analysts, with a target price of $19.27, and institutional …
Traders purchased a significantly high volume of put options on Oric Pharmaceuticals (NASDAQ:ORIC), indicating bearish sentiment or a desire for downside protection. This activity occurred despite the company's shares rising and analysts maintaining a "Moderate Buy" consensus rating with an average target price of …
ORIC Pharmaceuticals reported its Q2 2026 financial results, highlighting the initiation of the global Phase 3 Himalayas-1 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC), which is expected to enroll approximately 600 patients. The company also announced a collaboration with Bayer for the …
(RTTNews) - ORIC Pharmaceuticals, Inc. (ORIC), a clinical-stage oncology company, reported a wider net loss for the second quarter ended June 30, 2026, and provided updates on its clinical pipeline. Company Profile ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer …
* ORIC Pharmaceuticals press release [https://seekingalpha.com/pr/20604753-oric-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operational-updates] (ORIC [https://seekingalpha.com/symbol/ORIC]): Q2 GAAP EPS of -$0.38 misses by $0.02. * Cash, cash equivalents and investments totaled $387.6 million as of June 30, 2026, which includes $59.9 million in net proceeds raised from healthcare specialist funds during the …
Oric Pharmaceuticals, Inc. reported a wider net loss of $(77.3M) for the six months ended June 30, 2026, compared to $(66.4M) in the prior-year period, driven by continued R&D investment. Despite the increased net loss, diluted loss per share improved to $(0.72) from $(0.89). …
Oric Pharmaceuticals (NASDAQ:ORIC) saw its stock price fall by 5.2% on Monday, trading at around $10.50, with trading volume significantly below average. Despite missing its latest quarterly earnings estimates, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and an average price …
ORIC Pharmaceuticals announced its second quarter 2026 financial results and operational updates, including the initiation of the Himalayas-1 global Phase 3 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC). The company also reported a clinical trial collaboration with Bayer for darolutamide and anticipates …
Defilade Capital Management L.P. has acquired a new stake of 842,928 shares in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), valued at approximately $10.68 million, making it about 1.5% of their portfolio. Institutional investors collectively own 95.05% of the company, with many increasing their positions recently. Despite …
Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is exhibiting a mid-channel oscillation pattern with strong near and mid-term sentiment but a weak long-term outlook. AI models have generated three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels. The article …
Oric Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company with a potential upside of 77.77% according to analyst ratings. The company focuses on developing therapies to combat cancer resistance, with key candidates enozertinib and rinzimetostat in Phase 1b studies and strategic collaborations with Bayer …
Vivo Capital LLC reduced its stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 12.7% in the first quarter, selling 269,598 shares but still holding 1.85 million shares valued at $23.4 million. Despite institutional investors owning 95.05% of ORIC, the company reported a quarterly loss that …
Oric Pharmaceuticals has expanded its 2022 Inducement Equity Incentive Plan by 1,100,000 shares, increasing the total to 3,350,000 common shares. This amendment, effective July 28, 2026, aims to support equity awards for new hires or grants related to mergers and acquisitions. The information was …
This article lists various ETFs that hold stocks of Oric Pharmaceuticals, Inc., detailing their market value, weight, issuer, management style, focus, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover different investment strategies and market segments, from health care and biotechnology …
Oric Pharmaceuticals director Richard A. Heyman exercised stock options for 3,500 shares at $1.60 per share and subsequently sold 13,100 common shares at $12.02 per share on July 24, 2026. These sales, which included shares held through RAHD Capital, LLC, were executed under a …
This article provides an overview of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) financial information, specifically focusing on its revenue breakdown. It includes links to various financial statements, statistics, dividend information, and earnings reports. The content is presented as part of a financial data platform, likely …
The article provides a technical analysis of Oric Pharmaceuticals Inc (ORIC), examining various indicators and moving averages. It summarizes the current signals, noting a neutral signal based on moving averages and other technical indicators, with six buy signals from moving averages MA5 to MA200. …
This article provides a risk assessment for Oric Pharmaceuticals Inc (ORIC) based on various financial metrics. It details the company's volatility, daily returns, Sharpe ratio, maximum drawdown, and liquidity. The report offers investors a comprehensive statistical overview of ORIC's risk profile.
This article provides a detailed explanation of TradingKey's comprehensive stock scoring system for Oric Pharmaceuticals Inc (ORIC), despite indicating that no score is currently available due to insufficient data. It outlines how various scores are generated, including financial health, company valuation, earnings forecast, price …
Search by ticker symbol or company name and select a result to open its chart.